Please login to the form below

Not currently logged in
Email:
Password:

sarilumab

This page shows the latest sarilumab news and features for those working in and with pharma, biotech and healthcare.

Dupixent gains can’t keep Sanofi on a growth track

Dupixent gains can’t keep Sanofi on a growth track

At the same time, some much-trumpeted new launches like cholesterol drug Praluent (alirocumab) and arthritis drug Kevzara (sarilumab) have not delivered on their potential.

Latest news

More from news
Approximately 8 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Going the distance Going the distance

    Further down the line should come other Regeneron collaborations - first the IL-6 inhibitor sarilumab for rheumatoid arthritis and then dupilumab, which targets the IL-4 pathway that's responsible for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

WHITE PAPER: The increasing importance of clinical trial marketing advertising in patient recruitment
Learn why advertising is more important than ever in clinical studies...
The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s....
Early diagnosis underpins NHS cancer strategy
Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan...

Infographics